Further analyses of TP53 mutation in our patients are warranted because this data may provide prognostic values and the differential outcomes of patients with WR‐DLBCL, SN‐DLBCL, and LN‐DLBCL. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.